OraVerse

OraVerse is a brand name of phentolamine, approved by the FDA in the following formulation(s):

ORAVERSE (phentolamine mesylate - injectable; injection)

• 
  Manufacturer: SEPTODONT HOLDING
  
  Approval date: May 9, 2008
  
  Strength(s): 0.4MG/1.7ML ^[RLD]

Has a generic version of OraVerse been approved?

No. There is currently no therapeutically equivalent version of OraVerse available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OraVerse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Local anesthetic methods and kits
  Patent 6,764,678
  Issued: July 20, 2004
  Inventor(s): Eckard; Weber & Howard I.; Katz
  Assignee(s): Novalar Pharmaceuticals, Inc.
  Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
  
  Patent expiration dates:
  
  
  • May 11, 2021
    
    ✓ 
    Patent use: A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
  
  



• 
  Local anesthetic methods and kits
  Patent 6,872,390
  Issued: March 29, 2005
  Inventor(s): Weber; Eckard & Katz; Howard I.
  Assignee(s): Novalar Pharmaceuticals, Inc.
  Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
  
  Patent expiration dates:
  
  
  • May 11, 2021
    
    ✓ 
    Drug product
  
  



• 
  Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
  Patent 7,229,630
  Issued: June 12, 2007
  Inventor(s): Chen; Andrew X. & Knowles; Julius & Weber; Eckard
  Assignee(s): Novalar Pharmaceuticals, Inc.
  The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
  
  Patent expiration dates:
  
  
  • June 20, 2023
    
    ✓ 
    Drug product
  
  



• 
  Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
  Patent 7,569,230
  Issued: August 4, 2009
  Inventor(s): Chen; Andrew X & Knowles; Julius & Weber; Eckard
  Assignee(s): Novalar Pharmaceuticals, Inc.
  The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
  
  Patent expiration dates:
  
  
  • October 17, 2023
    
    ✓ 
    Patent use: A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
  
  



• 
  Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
  Patent 7,575,757
  Issued: August 18, 2009
  Inventor(s): Chen; Andrew X. & Knowles; Julius & Weber; Eckard
  Assignee(s): Novalar Pharmaceuticals, Inc.
  The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
  
  Patent expiration dates:
  
  
  • April 21, 2025
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 9, 2011 - NEW PRODUCT
  
  

See also...

• OraVerse Consumer Information (Drugs.com)
• OraVerse Advanced Consumer Information (Micromedex)
• Phentolamine Injection Advanced Consumer Information (Micromedex)
• Phentolamine Mesylate AHFS DI Monographs (ASHP)